Table 2.
Effect of EBRE on lipid profile (mg/dL) and atherogenic index in streptozotocin-induced diabetic rat. Results are expressed as mean ± SEM, n = 6.
| Groups | Cholesterol (mg/dL) | TG (mg/dL) | HDL (mg/dL) | LDL (mg/dL) | VLDL (mg/dL) | Atherogenic index |
|---|---|---|---|---|---|---|
| Control | 46.71 ± 5.59 | 40.57 ± 4.5 | 35.42 ± 3.50 | 2.81 ± 0.32 | 8.11 ± 0.90 | 0.34 ± 0.04 |
| Diabetic | 68.57 ± 5.8# | 68.14 ± 4.91## | 16.78 ± 1.61## | 4.26 ± 0.30# | 13.62 ± 0.98## | 0.74 ± 0.07### |
| Diabetic + GLI | 55.33 ± 3.92 | 58.16 ± 7.92 | 23.33 ± 1.42 | 3.64 ± 0.31 | 11.63 ± 1.58 | 0.55 ± 0.04* |
| Diabetic + EBRE (100 mg/kg) | 43.8 ± 3.35* | 38.4 ± 4.92** | 20.4 ± 3.15 | 2.33 ± 0.36** | 7.68 ± 0.98** | 0.49 ± 0.09** |
| Diabetic + EBRE (200 mg/kg) | 48.0 ± 3.19 | 42,4 ± 4.53* | 35.6 ± 4.74** | 3.66 ± 0.21 | 8.48 ± 0.90* | 0.37 ± 0.05*** |
| Diabetic + EBRE (400 mg/kg) | 47.42 ± 5.16* | 46.14 ± 3.88* | 36.42 ± 4.69** | 2.69 ± 0.25** | 9.22 ± 0.77* | 0.31 ± 0.06*** |
EBRE, Eryngium billardieri root extract; GLI, glibenclamide; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides; VLDL, very low-density lipoprotein. *P < 0.05, **P < 0.01, and ***P < 0.001 indicate significant differences in comparison with the diabetic group; #P < 0.05, ##P < 0.01, and ###P < 0.001 versus control group.